Role of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis of solid pancreatic and peripancreatic lesions: is onsite cytopathology necessary?  by Cherian, P. Thomas et al.
ORIGINAL ARTICLE
Role of endoscopic ultrasound-guided fine-needle aspiration in the
diagnosis of solid pancreatic and peripancreatic lesions: is onsite
cytopathology necessary?
P. Thomas Cherian, Prasoon Mohan, Abdel Douiri, Philippe Taniere, Rahul K. Hejmadi & Brinder S. Mahon
Department of Endoscopy and Imaging, Queen Elizabeth, University Hospital Birmingham NHS Trust, Edgbaston, Birmingham, UK
Abstracthpb_180 389..395
Objectives: The reported median diagnostic yield from endoscopic ultrasound (EUS) fine-needle aspi-
ration (FNA) cytology is 78% (range 39–93%). The aim of this study is to describe a single-centre
experience in the diagnostic work-up of solid pancreatic and peripancreatic masses without the benefit
of an onsite cytopathologist.
Methods: In a consecutive series of 429 EUS examinations performed over a 12-month period by a
single operator, 108 were on non-cystic pancreatic or biliary lesions. Data were collected prospectively
and the accuracy of FNA was assessed retrospectively using either surgery or repeat imaging as the
benchmark in the presence or absence of malignancy.
Results: Of the 108 FNAs, 102 (94%) were diagnostic, four were falsely negative (FN) and two were
atypical and considered equivocal. There were 78 pancreatic lesions, of which 65 were true positives (TP),
11 true negatives (TN) and two FN, giving an overall accuracy of 97% (76/78). Of nine periampullary
lesions, two were TP, six were TN and one was FN, giving an overall accuracy of 89% (8/9). The sensitivity,
specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of EUS-FNA for
pancreatic and periampullary lesions combined were 96%, 100%, 100% [95% confidence interval (CI)
95–100%], 85% (95% CI 62–97%) and 97%, respectively. There were 21 bile duct lesions, of which 10
were TP, eight TN, two atypical and one FN, giving an overall accuracy of 86% (18/21). The sensitivity,
specificity, PPV, NPV and accuracy of EUS-FNA for biliary lesions were 91%, 100%, 100% (95% CI
69–100%), 91% (95% CI 59–100%) and 95%, respectively.
Conclusions: The diagnostic accuracy of EUS-FNA for pancreatic lesions in our series was 97% and the
PPV for the three subgroups of lesion type was 100%; these figures are comparable with the best rates
reported in the literature, despite the absence of onsite cytopathology. These rates are potentially a direct
result of high-volume practice, dedicated endosonography and cytopathology. These results show that it
is possible to achieve high rates of accuracy in places where logistical issues make it impossible to
maintain a cytopathologist in the endoscopy suite. In addition, our results contribute to the limited,
collective global experience on the effectiveness of EUS-FNA in periampullary and biliary lesions.
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Introduction
In recent years, endoscopic ultrasound (EUS) and EUS-guided
fine-needle aspiration (EUS-FNA) have gained acceptance in the
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diagnosis of pancreatic and biliary pathology. Endoscopic ultra-
sound allows for the visualization of the pancreatic head, neck and
uncinate process from the duodenum, and the neck, body and tail
from the stomach. High-frequency ultrasound and the close prox-
imity of the transducer produce high-resolution images of the
pancreas and peripancreatic structures and can detect small
lesions that are discriminated with difficulty by computed tomog-
raphy (CT). Although several series have quoted high rates of
accuracy for EUS-FNA in the diagnosis of pancreatic lesions,1–10
the literature on EUS-FNA in biliary and ampullary lesions is
limited.11–17 Our study aims to assess the diagnostic accuracy of
EUS-FNA in pancreatic, periampullary and biliary lesions in a
single, high-volume centre in the absence of an onsite cyto-
pathologist. The paper also analyses the false negative cases in
detail to uncover learning points. We hope these results will con-
tribute to the limited, collective global experience on the effective-
ness of EUS-FNA in periampullary and biliary lesions, as data on
large numbers of these relatively rare lesions are difficult to amass
in individual centres performing EUS-FNA.
Materials and methods
All patients who underwent EUS-FNA performed for pancreatic,
biliary and periampullary lesions in a single hepato-biliary refer-
ral centre, over a 1-year period between March 2006 and March
2007, were identified and reviewed (Figs 1 and 2). Our patient
dataset represented a preselected cohort of patients who presented
with atypical histories or symptoms and equivocal CT findings
(e.g. no double duct sign or mass lesion) or who required a defini-
tive diagnosis although deemed unresectable or unfit for surgery.
Those patients with typical symptoms (e.g. painless obstructive
jaundice) and a resectable pancreatic mass on CT underwent
surgery without EUS. Prospectively collected data from the EUS
database and hospital records were used for analysis. All cystic
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pancreatic lesions (cystic tumours and pseudocysts) were
excluded as the diagnostic work-up for these lesions differed from
that for solid tumours.
Endoscopic ultrasound was performed under conscious seda-
tion (using midazolam and fentanyl) by a single experienced
operator using a curved linear array echo endoscope (Olympus
GF-UCT240-AL5; Olympus Corp., Tokyo, Japan), which allows
the visualization of the needle tract in real time. The instrument
has colour Doppler imaging built in, which helps with the iden-
tification and avoidance of vascular structures and, in some situ-
ations, aids diagnosis by quantifying the vascularity of the lesion
concerned. When the transducer had been positioned, the needle
catheter system (EchoTip, 22-gauge needle; Wilson-Cook
Medical, Inc.,Winston-Salem,NC,USA) was inserted through the
working channel of the echo endoscope and the needle advanced
into the target lesion under real-time ultrasound guidance. A
negative suction of 0–40 ml was applied to the FNA needle using
a syringe and the needle was then carefully moved back and forth
within the lesion. The aspirate was then expressed onto glass slides
and both air-dried and alcohol-fixed smears were prepared by the
endoscopist. A further aspirate was usually expressed into 15 ml of
CytoRich Red fixative. No cytopathologist was available in the
endoscopy suite to examine the adequacy of the sample. One to
four needle passes were performed as necessary to achieve an
adequate sample as determined by the echo endoscopist. All
smears were subsequently examined by two experienced, dedi-
cated cytopathologists with a special interest in pancreatic FNAs.
Figures 3 and 4 show example cytology.
The results of the FNAs were compared with the final diagnoses
as determined by specimen histology in patients undergoing
resection, and by serial imaging and clinical follow-up in non-
surgical patients. Lesions were considered to be benign if there was
no evidence of progression or resolution on serial imaging at 12
months. Any lesion which progressed on serial imaging or which
resulted in clinical deterioration or death was considered malig-
nant. In the current study, results were deemed to represent: a true
positive (TP) if both EUS-FNA and histology, serial imaging or
follow-up suggested malignancy; a true negative (TN) if both
EUS-FNA and histology or serial imaging suggested absence of
malignancy; a false positive (FP) if EUS-FNA showed tumour and
the resection specimen found no malignancy or no increase in
mass on imaging at 12 months, and a false negative (FN) if EUS-
FNA found no malignancy, but specimen histology, serial imaging
or follow-up confirmed the presence of malignancy.
It should be noted that the lesions were categorized into the
three groups defined above (pancreatic, biliary and periampullary
lesions) according to EUS findings rather than cross-sectional
imaging. Although lesions within the bile duct or ampulla were
relatively easy to categorize, intrapancreatic lesions were more
difficult. Here, the criterion of ‘mass centring on the bile duct or
ampulla’ (i.e. the site of uniform circumferential growth) was used
to assess the likely origin of the tumour. Therefore, it is possible
that some crossover may have occurred because some bile duct
cancers can be eccentrically centred around the bile duct.
Results
During the study period, 429 EUS-FNAs were performed for
various upper gastrointestinal lesions, of which 196 were for pan-
creatic and peripancreatic pathologies. Eighty-eight of these were
cystic lesions and were therefore excluded from the study, leaving
108 EUS-FNAs [78 (72%) were solid pancreatic, 21 (19%) were
bile duct and nine (8%) were periampullary lesions] in the final
study cohort (Figs 1 and 2). All but two of the 108 EUS were
completed as day patient procedures. Overall, 31 patients (29%)
had negative cytology (including ‘atypical’ results) on FNA; nine
(29%) of these patients underwent surgery and their diagnoses
were confirmed by histology, whereas the remaining 22 (71%)
underwent serial imaging rather than surgery.
Solid pancreatic lesions
In the 78 patients with solid pancreatic lesions, 50 (64%) of the
lesions were in the head, 13 (17%) in the body, 10 (13%) in the
neck and five (6%) in the tail of the pancreas (Fig. 2). The median
size of the lesions was 30 mm (range 20–80 mm). The median
number of passes during biopsy was two (range 1–4). Among the
pancreatic lesions, 65 (83%) EUS-FNAs yielded TP results after
comparison with the final diagnosis. The other 13 pancreatic
(A) (B)
Figure 3 Cytology showing adenocarcinoma cells: (A) pap stain; (B) clot preparation
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lesions included 11 TN, two FN and no FP results. The other
patients were followed up by imaging for12 months. One of the
two FN patients underwent a Whipple’s pancreaticoduodenec-
tomy and the other a jejunal resection. Their resection specimen
histology confirmed both the lesions to be gastrointestinal stromal
tumours (GISTs). Two FNA samples showed atypical cells on
cytology, which were later confirmed to represent chronic pancre-
atitis and pancreatic abscesses. The sensitivity, specificity, positive
predictive value (PPV), negative predictive value (NPV) and accu-
racy of EUS-FNA for pancreatic lesions are shown in Table 1 and
Fig. 5.
Periampullary lesions
Nine EUS-FNAs were performed for periampullary lesions. These
yielded two TP, six TN, no FP and one FN result for a lesion which
was later proven to be an adenocarcinoma following a Whipple’s
procedure. The sensitivity, specificity, PPV, NPV and accuracy of
EUS-FNA for periampullary lesions alone and combined with
pancreatic lesions are shown in Table 1.
Common bile duct lesions
A total of 21 patients underwent EUS-FNA for bile duct lesions.Of
these, 17 patients had undergone an endoscopic retrograde cho-
(A) (B)
(C)(D)
Figure 4 Clusters of cells with round nuclei and moderate cytoplasm confirming neuroendocrine neoplasm: (A) pap stain; (B) clot prepara-
tion; (C) positive synaptophysin; (D) positive chromogranin
Table 1 Pre- and post-test probabilities of endoscopic ultrasound-guided fine-needle aspiration in the three subgroups. Pre-test probabili-
ties are based on those reported by Heiken21
Pre-test probability EUS-FNA performance Post-test probabilities Overall performance
Disease prevalence
in the sample
(95% CI)
Sensitivity
(95% CI)
Specificity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
Accuracy
(95% CI)
Pancreatic lesions 86% 97% 100% 100% 85% 97%
(76–93%) (90–100%) (72–100%) (95–100%) (55–98%) (91–99%)
Periampullary lesions 33% 67% 100% 100% 86% 89%
(8–70%) (9–99%) (54–100%) (16–100%) (42–100%) (67–100%)
Bile duct lesions 52% 91% 100% 100% 91% 95%
(30–74%) (59–100%) (69–100%) (69–100%) (59–100%) (81–100%)
Pancreatic and periampullary lesions 80% 96% 100% 100% 85% 97%
(71–88%) (88–99%) (81–100%) (95–100%) (62–97%) (92–99%)
EUS-FNA, endoscopic ultrasound-guided fine-needle aspiration; PPV, positive predictive value; NPV, negative predictive value; 95% CI, 95%
confidence interval
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langiopancreatography (ERCP) prior to EUS. The EUS-FNA
results were TP in 10 patients, TN in eight and FN in one. Despite
being categorized as FN,a repeat EUS-FNAconfirmed the presence
of a cholangiocarcinoma in this particular patient. In two patients,
the EUS-FNA samples were indeterminate. Both of these were later
confirmed to be benign on repeat EUS-FNA performed at 6 and 12
weeks followed by serial imaging. Of the eight patients with TN
results, three underwent surgery and diagnosis was confirmed by
histology. Diagnoses in the remaining patients were again con-
firmed by repeat EUS-FNA at 6 and 12 weeks, and imaging
follow-up for 12months. The sensitivity, specificity, PPV,NPV and
accuracy of EUS-FNA for biliary lesions are shown in Table 1.
In the current series one patient suffered post-procedural
haemorrhage. This patient developed a peri-portal haematoma
and required surgical exploration. Another patient needed an
overnight stay in hospital for pain. No patients re-presented after
discharge from the day-case unit with pain or post-procedural
pancreatitis and neither was there any procedure-related
mortality. The final histology included, in addition to the adeno-
carcinomas, GISTs (n = 3), adenosquamous tumour (n = 1),
neuroendocrine tumours (n = 10) and tuberculosis (n = 1).
Discussion
Endoscopic ultrasound-guided FNA has emerged as a major diag-
nostic adjuvant in the management of pancreatic and biliary
lesions. Because of their anatomical location, relatively small pan-
creatic and bile duct lesions are often not amenable to percutane-
ous guided biopsy, although this limitation depends on the
experience of the individual operator and centre. Endoscopic
ultrasound-guided FNA is able to obtain tissue diagnosis in such
lesions in a relatively simple and safe manner, almost obviating the
need for surgery for tissue diagnosis. In addition, EUS-FNA sig-
nificantly decreases the likelihood of tumour seeding via the
needle track as the tissue planes traversed are usually part of the
potential surgical field.
Endoscopic ultrasound-guided FNA of pancreatic lesions was
first reported by Vilmann et al. in 1992,18 since when several large
series have reported sensitivities of EUS-FNA ranging from 74%
to 96% and specificity of close to 100%. Rocca et al. reported a
series of 246 patients in which the sensitivity and specificity of
EUS-FNA were 79% and 60%, respectively.1 In a series of 300
EUS-FNAs, Varadarajulu et al. noted that sensitivity of EUS-FNA
was significantly lower (74% vs. 91%) in patients with chronic
pancreatitis.2 The diagnostic accuracy and sensitivity of EUS-FNA
for solid pancreatic lesions in the current series are comparable
with the best rates reported in the literature. In both of the two
patients in whom FN results were obtained, the endoscopist noted
concern about either the sample or the lesion at the time of the
procedure. In the first patient, EUS showed a highly vascular mass
in the head of pancreas and FNA obtained a bloody aspirate which
did not show anymalignant cells. In view of the significant clinical
suspicion, this patient went on to have a pancreaticoduodenec-
tomy and the final histology confirmed a GIST. Endoscopic ultra-
sound in the second patient showed a dilated pancreatic duct up
to the level of the pancreatic head (bile duct thickening was noted
despite the absence of a stricture) and an ill-defined hypoechoic
lesion in the head of the pancreas, which was aspirated. Imaging
follow-up with serial CT demonstrated a pancreatic head mass of
increasing size and eventual liver metastases consistent with
malignancy. Co-morbidity had prevented initial surgery. Despite
the lack of malignant cells on cytology, endoscopic and clinical
features prompted further investigation. Although in theory it is
possible that an onsite cytopathologist might have enforced
further attempts to obtain representative cells, in practice the lack
of such a cytopathologist did not change our course of manage-
ment as no better aspirates were achieved in the first patient
despite multiple attempts and it was felt unnecessary to proceed
with further attempts in the second because the patient was unfit
for intervention.
Endoscopic ultrasound-guided FNA of biliary tract lesions has
been reported by many series to be useful, especially in determin-
ing the presence and extent of the often small lesions and the
involvement of regional lymph nodes.11–17 However, it is generally
acknowledged that EUS of the proximal bile duct is technically
more demanding as a result of the spiral relationship of the duct
to the duodenum as it travels past the duodenum. DeWitt et al.
studied 24 patients with a proximal biliary stricture and negative
ERCP brush biopsy.11 Endoscopic ultrasound enabled the visual-
ization of a mass in 23 (96%) patients and EUS-FNA had a sen-
sitivity of 77%.11 A review by Meara et al. of 46 patients with
suspected biliary tree malignancy found EUS-FNA to have sensi-
tivity of 87% and specificity of 100%.12 Sensitivity reported in
other studies varies between 43% and 89% and most of these
studies were conducted in circumstances that included an onsite
0%
20%
40%
60%
80%
100%
Pa
nc
re
at
ic
Bi
lia
ry
 tr
ac
t
Pe
ria
m
pu
lla
ry
FalseP
FalseN
TrueN
TrueP
Figure 5 Results for each of the three study cohorts according to
lesion location. Results for two patients in the bile duct cohort were
indeterminate and are not included. FalseP, false positive; FalseN,
false negative; TrueN, true negative; TrueP, true positive
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cytopathologist. In the current series, we found one FN result in a
patient in whom the US appearance was indeed suggestive of a
cholangiocarcinoma, but whose aspirate did not show malignant
cells, even when the procedure was repeated a month later. The
final diagnosis (cholangiocarcinoma) was confirmed by histology
following surgery. The two cases in which cytology was indeter-
minate were later confirmed to be benign with repeat EUS-FNA at
6 and 12 weeks and serial imaging.
Despite the results detailed above, it is important to highlight
the nine patients in the present study who underwent surgery
despite negative cytology and in whom diagnoses were confirmed
by histology at surgery. The procedures carried out in these
patients included gastric bypass (n = 2) and Roux-en-Y biliary
bypass (n = 7). All of these patients had chronic pancreatitis or
acute recurrent pancreatitis. In our experience, although chronic
pancreatitis is not diagnosed on cytopathological grounds, cyto-
pathology still has a very high PPV in detecting malignancy. One
of the difficulties for the EUS operator in this subgroup of patients
concerns knowing where to target sampling in the context of an
abnormal gland. The current study did not, however, specifically
look at this subset of pancreatic pathology on this occasion.
The literature on the use of EUS-FNA for ampullary tumours is
limited. In a series of 35 patients, Defrain et al. reported the sen-
sitivity and specificity of EUS-FNA for ampullary tumours to be
82% and 100%, respectively.19 In the current series, the one patient
in the periampullary lesion subgroup in whom an FN result was
obtained went on to have a resection and was found to have a
small focus of adenocarcinoma within the lesion, which would
have been unlikely to be sampled even with an onsite cytopatholo-
gist. By comparison, the diagnostic accuracy and sensitivity of
EUS-FNA for pancreatic lesions were greater than for biliary
lesions, which is in line with the published literature.
Endoscopic ultrasound-guided FNA is highly operator-
dependent.20 In the current series, a single endoscopist performed
all the procedures, which may have resulted in greater consistency
and contributed to the better diagnostic accuracy and sensitivity
achieved. No cytopathologist was present during the procedure to
evaluate the adequacy of the samples. Despite this, diagnostic rates
in the current series are comparable with the best rates reported in
the literature and most reported studies utilized an onsite cyto-
pathologist. The PPV for all three subgroups was 100%, which,
because it is greater than the actual prevalence in each subgroup,
suggests that EUS-FNA increases confidence in the confirmation
of the diagnosis. By comparison, CT has some limitations in
detecting these lesions, with published PPVs of 76–90%.21 In two
instances, bloody or inadequate samples were obtained, both of
which were recognized by the endoscopist at the time of biopsy. In
all instances of false interpretations, the endoscopist expressed
concerns about the sample at the time of the procedure. It is to be
noted that some of the credit for the results of the present study
reflect the experience of dedicated hepato-biliary pathologists,
who were able to make definite diagnoses on the basis of limited
samples.
Conclusions
The diagnostic accuracy of EUS-FNA for pancreatic lesions in the
current series was 97% and the PPVs for the three subgroups were
100%. These rates are comparable with the best rates reported in
the literature, despite the absence of onsite cytopathology. We
believe that these results are a direct result of high-volume prac-
tice and the substantial experience of dedicated endosonogra-
phers and cytopathologists. These results indicate that it is
possible to achieve high rates of accuracy, even when logistical
issues make it impossible to maintain a cytopathologist in the
endoscopy suite.
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